{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:30:18Z","timestamp":1771529418432,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12325-020-01528-2","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T10:02:51Z","timestamp":1605088971000},"page":"579-593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tiotropium\/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO\u00ae Trials"],"prefix":"10.1007","volume":"38","author":[{"given":"Klaus F.","family":"Rabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janwillem W. H.","family":"Kocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Tsiligianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"de la Hoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenqiong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary T.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga","family":"Wedzicha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"issue":"4","key":"1528_CR1","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.chest.2018.06.022","volume":"154","author":"M Cazzola","year":"2018","unstructured":"Cazzola M, Matera MG. POINT: should LAMA\/LABA combination therapy be used as initial maintenance treatment for COPD? Yes. Chest. 2018;154(4):746\u20138.","journal-title":"Chest"},{"issue":"4","key":"1528_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.chest.2018.06.024","volume":"154","author":"M Barrecheguren","year":"2018","unstructured":"Barrecheguren M, Miravitlles M. COUNTERPOINT: should LAMA\/LABA combination therapy be used as initial maintenance treatment for COPD? No. Chest. 2018;154(4):749\u201351.","journal-title":"Chest"},{"key":"1528_CR3","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2019. https:\/\/goldcopd.org\/wp-content\/uploads\/2019\/11\/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 15 Jun 2020."},{"issue":"9","key":"1528_CR4","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","volume":"201","author":"L Nici","year":"2020","unstructured":"Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56\u201369.","journal-title":"Am J Respir Crit Care Med"},{"key":"1528_CR5","unstructured":"National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2019. https:\/\/www.nice.org.uk\/guidance\/ng115\/chapter\/Recommendations#ftn.footnote_3. Accessed 15 Jun 2020."},{"issue":"5","key":"1528_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181\u201396.","journal-title":"Chest"},{"key":"1528_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2017.06.020","volume":"129","author":"L Calzetta","year":"2017","unstructured":"Calzetta L, Ora J, Cavalli F, Rogliani P, O\u2019Donnell DE, Cazzola M. Impact of LABA\/LAMA combination on exercise endurance and lung hyperinflation in COPD: a pair-wise and network meta-analysis. Respir Med. 2017;129:189\u201398.","journal-title":"Respir Med"},{"issue":"1","key":"1528_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","volume":"71","author":"Y Oba","year":"2016","unstructured":"Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting \u03b2-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71(1):15\u201325.","journal-title":"Thorax"},{"key":"1528_CR9","first-page":"CD012620","volume":"12","author":"Y Oba","year":"2018","unstructured":"Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2018;12:CD012620.","journal-title":"Cochrane Database Syst Rev"},{"key":"1528_CR10","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1007\/s12325-020-01411-0","volume":"37","author":"R Buhl","year":"2020","unstructured":"Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT. Efficacy of tiotropium\/olodaterol compared with tiotropium as a first-line maintenance treatment in patients with COPD who are na\u00efve to LAMA, LABA and ICS: pooled analysis of four clinical trials. Adv Ther. 2020;37:4175\u201389.","journal-title":"Adv Ther"},{"key":"1528_CR11","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1007\/s12325-020-01373-3","volume":"37","author":"R Buhl","year":"2020","unstructured":"Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT. Benefits of tiotropium\/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of the TONADO\u00ae and OTEMTO\u00ae studies. Adv Ther. 2020;37:3485\u201399.","journal-title":"Adv Ther"},{"issue":"1","key":"1528_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4104\/pcrj.2011.00102","volume":"21","author":"T van der Molen","year":"2012","unstructured":"van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA\/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012;21(1):101\u20138.","journal-title":"Prim Care Respir J"},{"issue":"6","key":"1528_CR13","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1183\/09031936.00179714","volume":"45","author":"A De Soyza","year":"2015","unstructured":"De Soyza A, Calverley PM. Large trials, new knowledge: the changing face of COPD management. Eur\u00a0Respir J. 2015;45(6):1692\u2013703.","journal-title":"Eur\u00a0Respir J"},{"issue":"4","key":"1528_CR14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.5811\/westjem.2018.4.38383","volume":"19","author":"CE McCoy","year":"2018","unstructured":"McCoy CE. Understanding the use of composite endpoints in clinical trials. West J Emerg Med. 2018;19(4):631\u20134.","journal-title":"West J Emerg Med"},{"issue":"1","key":"1528_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1081\/COPD-200053377","volume":"2","author":"JF Donohue","year":"2005","unstructured":"Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111\u201324.","journal-title":"COPD"},{"issue":"6","key":"1528_CR16","doi-asserted-by":"publisher","first-page":"e025776","DOI":"10.1136\/bmjopen-2018-025776","volume":"9","author":"HJ Alma","year":"2019","unstructured":"Alma HJ, de Jong C, Jelusic D, et al. Thresholds for clinically important deterioration versus improvement in COPD health status: results from a randomised controlled trial in pulmonary rehabilitation and an observational study during routine clinical practice. BMJ Open. 2019;9(6):e025776.","journal-title":"BMJ Open"},{"issue":"4","key":"1528_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407\u201315.","journal-title":"Control Clin Trials"},{"key":"1528_CR18","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/COPD.S133307","volume":"12","author":"AR Anzueto","year":"2017","unstructured":"Anzueto AR, Vogelmeier CF, Kostikas K, et al. The effect of indacaterol\/glycopyrronium versus tiotropium or salmeterol\/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325\u201337.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1528_CR19","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/COPD.S101612","volume":"11","author":"D Singh","year":"2016","unstructured":"Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium\/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413\u201324.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1528_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12931-020-01431-y","volume":"21","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Halpin DMG, Han MK, et al. Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. Respir Res. 2020;21(1):177.","journal-title":"Respir Res"},{"issue":"10","key":"1528_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa021322","volume":"350","author":"BR Celli","year":"2004","unstructured":"Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005\u201312.","journal-title":"N Engl J Med"},{"issue":"1","key":"1528_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12931-016-0361-4","volume":"17","author":"BR Celli","year":"2016","unstructured":"Celli BR, Decramer M, Liu D, Metzdorf N, Asijee GM, Tashkin DP. Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT\u00ae trial. Respir Res. 2016;17(1):48.","journal-title":"Respir Res"},{"issue":"1","key":"1528_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archinternmed.2007.37","volume":"168","author":"A Briggs","year":"2008","unstructured":"Briggs A, Spencer M, Wang H, Mannino D, Sin DD. Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. JAMA Intern Med. 2008;168(1):71\u20139.","journal-title":"JAMA Intern Med"},{"issue":"12","key":"1528_CR24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1164\/rccm.200902-0271OC","volume":"180","author":"RC Jones","year":"2009","unstructured":"Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(12):1189\u201395.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1528_CR25","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD\u00a02\u20134). Eur Respir J. 2015;45(4):969\u201379.","journal-title":"Eur Respir J"},{"issue":"suppl 54","key":"1528_CR26","first-page":"1014s","volume":"36","author":"F Maltais","year":"2010","unstructured":"Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract P5557]. Eur Respir J. 2010;36(suppl 54):1014s.","journal-title":"Eur Respir J"},{"key":"1528_CR27","first-page":"A7098","volume":"199","author":"R Buhl","year":"2019","unstructured":"Buhl R, de la Hoz A, Voss F, Singh D, Ferguson GT. Efficacy of tiotropium\/olodaterol compared with tiotropium in patients na\u00efve to LAMA, LABA and ICS: pooled analysis of four clinical trials. Am J Respir Crit Care Med. 2019;199:A7098.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"1528_CR28","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1080\/00325481.2015.1080589","volume":"127","author":"RA Panettieri Jr","year":"2015","unstructured":"Panettieri RA Jr. Bronchodilators, receptors and cross-talk: together is better? Postgrad Med. 2015;127(7):771\u201380.","journal-title":"Postgrad Med"},{"key":"1528_CR29","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.2147\/COPD.S146338","volume":"12","author":"P Rogliani","year":"2017","unstructured":"Rogliani P, Matera MG, Ora J, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis. Int J Chron Obstruct Pulmon Dis. 2017;12:3469\u201385.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1528_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pupt.2017.12.005","volume":"49","author":"JF Donohue","year":"2018","unstructured":"Donohue JF, Jones PW, Bartels C, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2018;49:11\u20139.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"1528_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12931-018-0928-3","volume":"19","author":"IP Naya","year":"2018","unstructured":"Naya IP, Tombs L, Muellerova H, Compton C, Jones PW. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res. 2018;19(1):222.","journal-title":"Respir Res"},{"issue":"3","key":"1528_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/ACI.0b013e3283609831","volume":"13","author":"D Curran-Everett","year":"2013","unstructured":"Curran-Everett D, Milgrom H. Post-hoc data analysis: benefits and limitations. Curr Opin Allergy Clin Immunol. 2013;13(3):223\u20134.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1528_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2147\/COPD.S196383","volume":"14","author":"D Singh","year":"2019","unstructured":"Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A. Extrafine triple therapy delays COPD clinically important deterioration vs ICS\/LABA, LAMA, or LABA\/LAMA. Int J Chron Obstruct Pulmon Dis. 2019;14:531\u201346.","journal-title":"Int J Chron Obstruct Pulmon Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01528-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-020-01528-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01528-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T21:27:52Z","timestamp":1612301272000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-020-01528-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1528"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01528-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"13 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}